Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for a wide range of chronic diseases, leveraging its structure-based drug discovery platform. The lead product candidate, aleniglipron (GSBR-1290), an oral selective GLP-1R agonist, is in five ongoing clinical studies for obesity, overweight, and related conditions. The Phase 2b ACCESS study for aleniglipron demonstrated a placebo-adjusted mean weight loss of 11.3% with the 120 mg dose at 36 weeks. The exploratory ACCESS II study showed a placebo-adjusted mean weight loss of 15.3% with the 240 mg dose at 36 weeks. A lower starting titration dose of 2.5 mg in the ACCESS Open Label Extension (OLE) and Body Composition studies significantly improved tolerability, with no adverse event-related discontinuations at the initial 2.5 mg or subsequent 5 mg dose. Aleniglipron also demonstrated clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and hemoglobin A1c (HbA1c) (-0.28% to -0.37%). The company has two oral small molecule amylin receptor agonists: ACCG-2671, currently in Phase 1 clinical development, and ACCG-3535, selected as a second development candidate, both showing promising preclinical data. Net loss for the year ended December 31, 2025, was $141.2 million, an increase from $122.5 million in 2024, contributing to an accumulated deficit of $470.3 million. Research and development expenses increased by 107% to $225.3 million in 2025, primarily due to increased clinical trial costs, preclinical R&D, personnel, and a $9.0 million milestone payment to Schrdinger. General and administrative expenses rose by 25% to $61.6 million in 2025, driven by increased headcount and public company operational costs. The company received $100.0 million in other license income from Genentech, Inc. and F. Hoffmann-La Roche Ltd (GNE) for a non-exclusive license of certain GLP-1 receptor agonist patents, distinct from aleniglipron. A $10.2 million gain was recognized from the sale of early-stage non-metabolic and non-obesity assets under the Exelixis Agreement. As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $1,446.2 million, which is expected to fund projected operations and key clinical milestones through the end of 2028, excluding pre-commercialization activities.